Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
Read original at benzingaStocks · News reference
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 5:45 PM
- Checked
- Aug 17, 2026, 5:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.
Read original at benzingaMesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same
Read original at benzingaMesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Limited reported strong financial results for FY2026 with total revenue of US$120.3 million, driven by successful RYONCIL commercial launch generating US$115.2 million in net revenue. The company completed patient treatment in its Phase 3 trial for chronic low back pain (rexlemestrocel-L), with results expected mid-2027. Net losses were reduced 44% to US$57.5 million. The company is expanding RYONCIL into adult markets and developing next-generation CAR-MSC and oncolytic virus technologies.
Read original at globenewswire-inc